A replicable, disciplined longevity medicine model.
We measure health and follow it over time, in our own facilities and inside already-authorized clinics. Low-capital, replicable model.
Amounts, scope and economic terms are in the confidential dossier, not on the public website.
What kind of operation this is, in four points.
No public figures, but clear from the start: so you can tell whether this is your kind of operation. By "dossier" we mean the confidential documentation for investors.
| What it is | A co-investment in the facility and a selective partnership, not a public fundraising. The group puts in its own capital first; the order of magnitude of the commitment over time also includes the leverage of the subsidised Invitalia call and selective forms of co-investment in the facility, so it is not all the partners' risk capital. |
| What return it seeks | Two components: a recurring cash flow from the network of clinics, and the value of the assets built over time. |
| Where we are | At the launch stage. Today the strength is the model, the method and the people, not growth numbers to show off. |
| How to get access | By qualified request: you write to us, we assess, and if there is alignment we give you access to the confidential dossier with figures and terms. |
Amounts, scope and economic terms are in the confidential dossier, not on the public website.
The thesis, in three lines.
Medicine is shifting from treating disease to prevention that can be measured. Demand for quality longevity services is growing steadily.
Today this demand is served poorly: one-off check-ups, aesthetics disguised as prevention, a fragmented offering, no continuity after the first report.
Longevilife brings three things together, tests and biomarkers, the history of the data over time, and a journey that continues, and takes them inside third-party clinics that are already licensed, with a model that can be repeated.
Three forces converging now.
Here the forces are described qualitatively. The numbers and sources, always attributed to third parties, are on the Market validation page.
Structural shift
Medicine is moving from treating disease to measurable prevention. It is a long-term change, not a fad.
Sector capital
International capital is concentrating on models of measurable longevity and scalable prevention.
Scientific maturity
Biomarkers and indicators validated on large cohorts now make a serious method possible, not promises.
The numbers and sources are on the Market validation page.
The heart of the thesis is not a single centre, but a model that enters inside already-licensed clinics (we call "Hub" the longevity unit inside an already-active clinic). This avoids much of the capital and time of building a clinic from scratch, and the model can be repeated.
| Longevilife brings | The partner clinic brings |
|---|---|
| Brand and method | Existing spaces and equipment |
| Clinical protocols and training | Doctors and medical responsibility |
| Dedicated people and operational management | Billing of the services |
| Patient acquisition and nutraceuticals | Authorisations already in place |
Example of what the end client receives: a first complete measurement (tests and biomarkers), a journey built on their data, and re-tests over time to compare results and adjust course, not a one-off check-up.
The three qualities of the model.
Little capital for investors
It relies on authorisations and clinical spaces that already exist, instead of building them from scratch. For us and for the clinic, entry costs less and arrives sooner.
Replicable
A defined format, repeatable across multiple facilities without reinventing it each time.
Disciplined
A method based on evidence and communication without exaggerated promises: what lets a serious doctor put their name to it.
We write it the way we think it: today what counts is the model, the method and the people, not growth numbers to show off.
For healthcare groups and strategic operators.
If you represent a healthcare group, a sector operator or a fund considering a strategic position, the Longevilife model is designed to integrate with networks of already-existing clinics and to grow by opening new Hubs one after another. We open a confidential and selective conversation, on a basis of mutual acquaintance.
- Integrates with networks of already-existing clinics.
- Grows by opening new Hubs one after another.
A project led by people, not by promises.
A team with clinical, scientific and development expertise. The governance distinguishes two roles: scientific direction (scientific vision, method and protocols) and an independent medical direction to be appointed, registered with the medical board, with clinical responsibility for the facility. This way the clinical role stays separate from the business role. Names and roles of the team are in the confidential material.
Estimates and projections are from third parties, cited with source and date. They remain projections, not predictions of results.
- —Global anti-aging and longevity market.According to Grand View Research, estimated at around 100 billion dollars in 2025 and projected toward roughly 400 billion by 2033, with an estimated compound annual growth rate of around 18%. (Source: Grand View Research, 2025 data.)
- —Private healthcare spending in Italy.According to data cited by the Italian State General Accounting Office, private healthcare spending exceeds 40 billion euros, growing year on year, in a context of progressive defunding of public healthcare. (Source: State General Accounting Office; analysis based on 2024 data.)
Rounds reported by the trade press, cited with source and date. They are third-party deals: they validate the field, not Longevilife’s services.
- —Neko Health, Series B.According to reports in the trade press, it raised a round of around 260 million dollars at a valuation of around 1.8 billion. (Source: trade communications and press, January 2025.)
- —Function Health, Series B.According to reports, it raised a round of around 298 million dollars at a valuation of 2.5 billion. (Source: trade press, November 2025.)
International venture capital is funding models of measurable longevity and scalable prevention. It is a signal about the field, not a prediction about Longevilife’s results.
Peer-reviewed evidence in the field. Each indicator is documented or associated with health outcomes, never presented as a promise of results.
- —Grip strength and mortality.The association is documented in very large cohorts. (Source: UK Biobank, BMJ 2018, n ≈ 500,000.)
- —Glycated haemoglobin (HbA1c).Associated with mortality and cardiovascular events. (Source: EPIC-Norfolk, Annals of Internal Medicine, 2004.)
- —VO₂max.Among the strongest predictors of survival according to the literature. (Source: Mandsager et al., JAMA Network Open, 2018.)
- —Epigenetic clocks.Indicators such as GrimAge and DunedinPACE are the subject of established research on biological aging. (Source: Duke/Columbia research groups; Horvath.)
Why Longevilife, and why now.
Capital, demand and science validate the field globally. In Italy a clinically serious, continuous and data-driven longevity medicine does not yet exist; in Europe it exists but is fragmented. Longevilife brings a disciplined, replicable model that requires little capital into a market that is ready.
- Little capital: the model relies on already-licensed clinics, instead of building new ones.
- First in Italy: we are the first to bring a model built on data and on continuity of journey, not on the single test.
- No exaggerated promises: we communicate only what research documents, and we state our limits.
The data reported on this page comes from third-party sources and refers to the market, the capital and the scientific research of the longevity sector. It validates the field in which we operate, not Longevilife’s services. The sources are indicated next to each figure; the market estimates are third-party projections and do not constitute predictions of Longevilife’s results.
The complete dossier is confidential.
Thesis, model, figures for each type of facility and the scope of the project are in a dossier that we share on qualified request. Access is manual and selective.